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Requirements for global elimination of hepatitis B: 
a modelling study
Shevanthi Nayagam, Mark Thursz, Elisa Sicuri, Lesong Conteh, Stefan Wiktor, Daniel Low-Beer, Timothy B Hallett
Summary
Background Despite the existence of eﬀ ective prevention and treatment interventions, hepatitis B virus (HBV) 
infection continues to cause nearly 1 million deaths each year. WHO aspires to global control and elimination of HBV 
infection. We aimed to evaluate the potential impact of public health interventions against HBV, propose targets for 
reducing incidence and mortality, and identify the key developments required to achieve them.
Methods We developed a simulation model of the global HBV epidemic, incorporating data on the natural history of 
HBV, prevalence, mortality, vaccine coverage, treatment dynamics, and demographics. We estimate the impact of 
current interventions and scaling up of existing interventions for prevention of infection and introducing wide-scale 
population screening and treatment interventions on the worldwide epidemic.
Findings Vaccination of infants and neonates is already driving a large decrease in new infections; vaccination has 
already prevented 210 million new chronic infections by 2015 and will have averted 1·1 million deaths by 2030. 
However, without scale-up of existing interventions, our model showed that there will be a cumulative 63 million new 
cases of chronic infection and 17 million HBV-related deaths between 2015 and 2030 because of ongoing transmission 
in some regions and poor access to treatment for people already infected. A target of a 90% reduction in new chronic 
infections and 65% reduction in mortality could be achieved by scaling up the coverage of infant vaccination (to 90% 
of infants), birth-dose vaccination (to 80% of neonates), use of peripartum antivirals (to 80% of hepatitis B e antigen-
positive mothers), and population-wide testing and treatment (to 80% of eligible people). These interventions would 
avert 7·3 million deaths between 2015 and 2030, including 1·5 million cases of cancer deaths. An elimination 
threshold for incidence of new chronic infections would be reached by 2090 worldwide. The annual cost would peak 
at US$7·5 billion worldwide ($3·4 billion in low-income and lower-middle-income countries), but decrease rapidly 
and this would be accelerated if a cure is developed.
Interpretation Scale-up of vaccination coverage, innovations in scalable options for prevention of mother-to-child 
transmission, and ambitious population-wide testing and treatment are needed to eliminate HBV as a major public 
health threat. Achievement of these targets could make a major contribution to one of the Sustainable Development 
Goals of combating hepatitis.
Funding Medical Research Council.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
In 2014, the World Health Assembly requested WHO to 
examine the feasibility of, and strategies needed for, the 
elimination of hepatitis B virus (HBV) and hepatitis C 
virus (HCV) infections.1 This substantial political 
momentum is entirely proportionate to the estimated 
magnitude of the global burden, with viral hepatitis 
ranked as the seventh highest cause of mortality 
worldwide and responsible for 1·4 million deaths per 
year (roughly 687 000 deaths due to HBV and 704 000 due 
to HCV).2 However, despite being similar in scale to the 
1·29 million deaths annually due to HIV, 1·34 million 
annually due to tuberculosis, and 850 000 deaths annually 
due to malaria,3 viral hepatitis has been a relatively 
neglected area.4,5
Fortunately, a wide range of interventions are now 
available to prevent and treat HBV infection. Early 
childhood transmission can be prevented with a highly 
eﬀ ective infant vaccine.6 Mother-to-child transmission at 
birth can be almost completely eliminated by the 
administration of birth-dose vaccination, intravenous 
hepatitis B immunoglobulin, and peripartum antiviral 
therapy for mothers with high viral load.7,8 For individuals 
who are already chronically infected with HBV, treatment 
with antivirals can suppress viral replication and 
substantially reduce the risk of progression to liver 
cirrhosis and liver cancer.9,10
However, these interventions are not fully used. 
Coverage of infant vaccination is high in many regions 
such as east Asia and north Africa and the Middle East 
(92–96% in 2013), but continues to lag behind in others, 
most notably central Africa (56% in 2013).11 Birth-dose 
vaccine coverage is generally lower than infant vaccination 
worldwide, although a few countries, including China, 
have achieved over 95% coverage.11 Treatment coverage is 
low in most high-burden settings (eg, sub-Saharan Africa) 
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and, where available, is typically provided to patients 
presenting for care with advanced disease and is not 
accompanied by active outreach or routine testing.12
Action on HBV worldwide will need the scale-up of 
these interventions, but the magnitude of impact that is 
achievable, the budgetary implications of scaling up 
interventions, and the emphasis with which these 
diﬀ erent approaches should be promoted and developed 
in the diﬀ erent regions is not yet clear.
A number of useful deﬁ nitions of elimination exist. 
The 2015 Sustainable Development Goals (SDGs) include 
goals for the elimination of HIV, tuberculosis, and 
malaria, each of which uses a threshold deﬁ nition of 
what constitutes elimination as a public health threat. 
Using this approach, we chose to adopt a threshold 
approach of fewer than ten per million people for 
incidence and fewer than 50 per million HBV-related 
deaths, which is intermediate to the levels used for 
tuberculosis and HIV. 
Using a mathematical model, we aimed to evaluate the 
projected future course of the global epidemic of HBV 
infection and evaluate the impact of historical 
interventions. We also aimed to assess the impact of 
scaling up available public health prevention and 
treatment interventions on incidence, prevalence, and 
mortality due to HBV, set potential targets for elimination, 
and identify key developments needed to achieve them.
Methods
Model structure
We constructed a dynamic, deterministic mathematical 
trans mission model of the global hepatitis B epidemic 
structured by age, sex, and region. The model is 
composed of 21 Global Burden of Disease world regions, 
and is ﬁ tted to data on hepatitis B surface antigen 
(HBsAg)13 and hepatitis B e antigen (HBeAg)14 prevalence, 
at two timepoints, and liver cancer deaths15 for each 
region independently. The model incorporates region-
speciﬁ c demographic data on population size, mortality, 
and fertility schedules,16 coverage of existing interventions 
(infant vaccination,11 birth-dose vac cination,11 and 
treatment availability12), and assumptions about the 
natural history of HBV. In the model, mother-to-child 
transmission, transmission between children, and 
transmission across the whole population (which 
includes other forms of transmission including sexual 
and iatrogenic) are included, the relative strengths of 
which are inferred through the calibration procedure 
(appendix p 35). We did not explicitly model the relative 
contribution of diﬀ erent routes of iatrogenic transmission 
(eg, blood transfusion, unsafe injection practices) 
because this is a relatively small proportion of all 
transmission of HBV worldwide at present and infection 
in adulthood is less likely to lead to chronic infection.
We did a literature review, which informed the HBV 
natural history scheme in the appendix (p 36). Brieﬂ y, we 
used twelve mutually exclusive health states, which 
includes seven untreated chronic hepatitis B stages: 
immune tolerant, immune reactive (HBeAg-positive 
chronic hepatitis), inactive carrier, HBeAg-negative 
chronic active hepatitis, compensated cirrhosis, decom-
pensated cirrhosis, and hepatocellular carcinoma.17,18 
Immune reactive and HBeAg-negative chronic hepatitis 
B are states of chronic active hepatitis, with high or 
Research in context
Evidence before this study
We searched PubMed for studies published up to Sept 4, 2015, 
with the terms “hepatitis B”, “HBV”, or “CHB”, and “modelling”, 
“modeling”, or “model”. Previous hepatitis B virus (HBV) 
modelling and epidemiological analyses have focused on the 
evaluation of the potential future impact of infant vaccination 
strategies. These studies have mainly been done at a country 
level, concentrated on prevalence and incidence outcomes, 
rather than morbidity and mortality, and have not examined 
costs of intervention. Only one study presented an HBV model 
on a global level, which examined the relationships between 
vaccination coverage and projections of deaths due to cirrhosis 
and liver cancer. However, this model did not include prevention 
of mother-to-child transmission (PMTCT) or treatment 
interventions, and the model was based on assumptions of a 
linear response between vaccination and disease incidence, 
which could underestimate the intervention impact.
Added value of this study
Our study is unique in providing a worldwide view of the 
hepatitis B epidemic and the potential impact and costs of a 
comprehensive set of interventions (vaccination, PMTCT, 
screening, and treatment). Furthermore, our study incorporates 
the latest data and understanding of HBV disease progression 
and treatment eligibility, as well as all available data on HBV 
prevalence and mortality and programme coverage indicators. 
Our results show that although much progress has been made 
through vaccination, a scale-up of both prevention and 
treatment interventions is needed to reduce HBV as a public 
health threat.
Implications of all the available evidence
This study frames and quantiﬁ es major issues that should be 
addressed as momentum increases to tackle HBV globally. It 
proposes targets around which strategies could develop and 
identiﬁ es the main implementation research priorities and 
innovations needed to achieve this goal. This study responds 
directly to the World Health Assembly resolution that calls for 
an evaluation of feasibility of global elimination and control of 
hepatitis, and Sustainable Development Goal 3.3 that aims to 
combat hepatitis and other infectious diseases. 
See Online for appendix
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ﬂ uctuating viral load, elevated transaminase 
concentration, and evidence of ﬁ brosis. Along with 
compensated cirrhosis and decompensated cirrhosis, 
these stages are considered eligible for treatment, as per 
international guidelines.18,19
Costing model
A costing model was developed to estimate total 
intervention costs, which assigned region-speciﬁ c, time-
constant costs to each of the intervention components. The 
cost package included consumables plus delivery of the 
intervention and relevant outreach costs (appendix p 26). 
Cost inputs were based on costing data from published 
literature and databases. Primary cost results are presented 
in US$ (2014) to allow comparison with existing literature. 
An alternative approach, using purchasing power parity 
adjustments for non-traded resources was also done to 
correct for distortions in direct gross domestic product 
comparisons (presented in international$). Full costing 
methods are provided in the appendix. Antiviral drug price 
was based on observed global minimum pricing, assuming 
price reductions and in anticipation that costs can fall to 
these levels worldwide. The costs avoided through care 
costs for cirrhosis and cancer were not included because 
global-level data on these costs are scarce. A discount rate 
of 3% per year was applied when computing present 
values of a stream of future costs.20
Interventions scenarios
Five scenarios were used to quantify the eﬀ ect of scaling 
up available interventions from 2015 (table). Additionally, 
we include a status quo scenario, in which the coverage 
of all interventions remains at their current levels, and a 
no historical intervention scenario, in which the impacts 
of all interventions are removed. In the infant vaccination 
scenario, coverage of infant vaccination is scaled up 
linearly over 5 years to 90% (or maintained at higher 
than 90%, if already achieved), consistent with the WHO 
Global Action Vaccine Plan targets for vaccination 
coverage of 90% or higher by 2020.21 Addition of birth-
dose vaccination involves a linear scale-up over 5 years of 
birth-dose vaccination coverage in neonates with HBsAg-
positive mothers to 80% (or maintained at current levels 
if coverage higher than 90% has already been achieved) 
and the scenario with addition of peripartum antivirals 
involves a scale-up over 10 years so that 80% of HBeAg-
positive mothers receive peripartum antivirals in the last 
trimester of pregnancy by 2025. The addition of test and 
treat includes testing, linkage, and adherence inter-
ventions necessary to provide successful treatment with 
durable viral suppression to 80% of people becoming 
eligible,19 a value that signiﬁ es universal health coverage 
across a range of essential health services, and has 
commonly been used as a target for universal access to 
HIV treatment.22 Treatment is assumed to be based on 
either tenofovir or entecavir and includes monitoring 
and adherence as is suﬃ  cient for patients to maintain 
viral suppression. Adverse events and contraindications 
are rare and were not considered in the model. We also 
included a hypothetical curative strategy whereby 
patients on treatment can be given a one-time 
intervention that results in sustained viral suppression 
or loss of HBsAg. Assumptions used to represent the 
eﬃ  cacy of each intervention are outlined in the 
appendix (p 5).
We ﬁ rst used the model to generate predictions about 
the incidence of new chronic HBV carriage, prevalence 
of people living with chronic HBV, and deaths due to 
Infant vaccination 
coverage
Birth-dose 
vaccination coverage
Coverage of peripartum 
antivirals for HBeAg-
positive mothers*
Access to treatment† Cure 
expected
No historical intervention None None None None No
Status quo Continues at 
current levels‡
Continues at current 
levels‡
No coverage Continues at current levels 
(categorised by region)§
No
Infant vaccination 90%¶|| Continues at current 
levels‡
No coverage Continues at current levels 
(categorised by region)§
No
Infant vaccination + birth-dose 
vaccination
90%¶|| 80%¶|| No coverage Continues at current levels 
(categorised by region)§
No
Infant vaccination + birth-dose 
vaccination + PPT
90%¶|| 80%¶|| 80%** Continues at current levels 
(categorised by region)§
No
Infant vaccination + birth-dose 
vaccination + PPT + treatment
90%¶|| 80%¶|| 80%** 80%†† (linear scale-up 
2015–25)
No
Infant vaccination + birth-dose 
vaccination + PPT + treatment + cure
90%¶|| 80%¶|| 80%** 80%†† (linear scale-up 
2015–25)
2025
Assumptions used to represent the eﬃ  cacy of each intervention are outlined in the appendix (p 5). HBeAg=hepatitis B e antigen. PPT=peripartum antiviral therapy (given to 
HBeAg-positive mothers). *Peripartum antivirals are given to HBeAg-positive mothers only. Hepatitis B immunoglobulin not implicitly modelled because data were not 
available, but continues at current levels. †Includes case ﬁnding and treatment. ‡WHO data11 on vaccination coverage up to 2013. §Global Policy report12 on viral hepatitis and 
expert opinion. ¶If the regional coverage is already above the target level, it remains at current high level. || Linear scale-up 2015–20. **Linear scale-up 2015–25. ††80% 
incorporates a strategy of 90% case ﬁnding, 95% linked to care, 95% durable viral suppression.
Table: Intervention strategies modelled, coverage levels, and scale-up times
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HBV under assumptions that interventions remain at 
current levels (status quo). We then compared this 
scenario to a scenario when all historical interventions 
were removed to estimate how the epidemic would have 
unfolded if nothing had been done previously. We then 
used the model to estimate the impact of scaling up 
prevention and treatment inter ventions by considering 
the ﬁ ve alternative strategies. Incidence refers to 
incidence of new chronic HBV carriage, rather than 
acute infection, throughout this Article.
Sensitivity analysis
Sensitivity analysis was done by varying the main 
eﬃ  cacy parameters (ﬁ rst value representing the lower 
limit used for the sensitivity analysis and the second 
value representing the default value used in the model); 
eﬃ  cacy of infant vaccination against chronic carriage of 
88–95%,6,23 eﬃ  cacy of birth-dose vaccination against 
mother-to-child transmission if maternal HBeAg 
negative of 85–96%,7 eﬃ  cacy of birth-dose vaccination 
against mother-to-child transmission if maternal 
HBeAg positive of 75–83%,24–28 and eﬃ  cacy of antiviral 
treatment on prevention of mother-to-child transmission 
(PMTCT) of 85–99% and adherence to antiviral 
treatment of 65–90%. These lower limits of ranges of 
eﬃ  cacy parameters were chosen to represent what 
could happen in a worst-case situation and are based on 
conservative assumptions.
Role of funding source
The funder had no role in data analysis, data 
interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
The model reproduces the global epidemiology of HBV 
well (ﬁ gure 1) and several key epidemic patterns are 
noted: prevalence of HBsAg (a marker of chronic 
infection) is highest in west Africa, prevalence of 
HBeAg tends to be higher in east Asian regions than in 
African regions, and the number of cancer deaths 
increases sharply with age and is highest in east Asia, 
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 Figure 1: Model calibration (data vs modelled results)
Calibration of the model outputs to available epidemiological data from each of the 21 world regions. Data versus modelled results by region for HBsAg prevalence 
(ages 5–70 years), HBeAg prevalence in HBsAg-positive people (from birth to age 40 years), and HBV-related cancer deaths (all ages in 2012). For HBsAg prevalence, 
individual data points are presented for each of the 21 regions, both sexes, and three age groups (5–10 years, 10–40 years, and 40–70 years) at two timepoints 
(1990 and 2005). For HBeAg prevalence, individual data points are presented for each of the 21 regions, both sexes, and three age groups (0–10 years, 20–30 years, 
and 30–40 years) at two timepoints (1990 and 2005). The lines are colour-coded to represent the seven diﬀ erent continent groupings. Individual regional calibration 
ﬁ gures are in the appendix (p 45). HBsAg=hepatitis B surface antigen. HBeAg=hepatitis B e antigen. HBV=hepatitis B virus.
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where prevalence is high and treatment is not widely 
available.
The modelled global estimate of HBV-related mortality 
(850 000 deaths in 2010) and the number of people living 
with HBV (290 million people in 2010) are both consistent 
with previously published sources.1,3,29 Modelled incidence 
of new chronic infections in 2010 is 6·7 million. In 2010, 
30% of the HBV-related deaths, 40% of the people living 
with HBV, and 70% of new chronic infections occurred in 
the ﬁ ve regions with most of the low-income countries.
The model projects that at status quo, there will be 
4·3 million new chronic infections, 270 million people 
living with HBV, and 1 million deaths due to HBV in the 
year 2020 (ﬁ gure 2). Between 2020 and 2050, the number 
of new infections per year will drop by 70% to 1·3 million 
infections per year, as a result of sustained vaccination 
coverage. By 2050, the number of people living with 
infection will decrease by 40% to 165 million, because of 
reducing incidence and the continued death of 
individuals infected with HBV. The number of HBV-
related deaths per year will increase in the coming years, 
reaching 1·14 million deaths per year in 2034, because of 
ageing cohorts of infected people. HBV-related deaths 
will then decline to 1·06 million deaths per year by 2050.
Vaccination scale-up is already having a large eﬀ ect on the 
epidemic (ﬁ gure 2). Without any infant or birth-dose 
vaccination, there would be 25 million new cases in 2020; 
meaning that interventions have already reduced new cases 
by 83% and cumulatively averted 310 million new cases 
between 1990 and 2020. The impact is largely mediated by 
the eﬀ ects of infant vaccination (appendix p 37). By our 
deﬁ nition, some regions with high infant vaccination 
coverage are projected to reach elimination of new infections 
between 2060 and 2070, even with status quo coverage 
levels (eg, east Asia, central Asia, eastern Europe, and the 
Caribbean). Infant vaccination is highly eﬀ ective at reducing 
chronic HBV carriage in children, but does not directly 
aﬀ ect the risk of acquisition in neonates. A consequence of 
that is the proportion of new chronic cases that arise 
through mother-to-child transmission is set to increase 
substantially, from 16% in 1990 to 50% in 2030 (ﬁ gure 2). 
Therefore, in most regions, additional interventions will be 
required to further reduce infection rates.
Furthermore, existing interventions have not yet 
substantially reduced the number of individuals living 
with chronic infection (30% reduction in 2020 vs no 
intervention) or HBV-related deaths (4% reduction in 2020 
vs no intervention), because treatment has not been scaled 
up to a global level, which is needed to reduce the risk of 
death in people already infected. Also, the long interval 
between acquisition of chronic carriage of HBV and death 
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Figure 2: Epidemic projections for HBV
(A) HBV incidence of new cases of chronic HBV, prevalence of HBV, and deaths 
caused by HBV in the status quo scenario (all interventions remain at current 
levels; blue line) and no historical intervention scenario (assumed no 
interventions have ever been applied; black line). (B) Ages of people in which new 
cases of chronic HBV occur in the status quo scenario. HBV=hepatitis B virus.
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means that the population of people living with HBV 
changes slowly in response to intervention.
Without further scale-up of interventions, the number 
of people living with HBV is going to remain at the same 
high levels for 40–50 years and there will still be a 
cumulative 63 million new chronic infections and 
17 million HBV-related deaths between 2015 and 2030. 
However, scaling up existing interventions could lead to 
a 90% reduction in incidence of new chronic infections 
and 65% reduction in mortality by 2030 worldwide 
(ﬁ gure 3).
In the ﬁ rst scenario, scaling up infant vaccination to 90% 
globally would avert 4·3 million new infections between 
2015 and 2030 compared with the status quo scenario. 
Addition of scaling up of birth-dose vaccination and 
peripartum antiviral therapy to 80% enhances this impact, 
preventing a further 19·3 million new infections, with 
most of that incremental impact achieved by birth-dose 
vaccination alone (18·7 million new cases prevented). The 
large incremental impact due to PMTCT intervention is 
because of the fact that vertical trans mission increases in 
relative importance as other transmission routes are 
reduced. None of these prevention strategies reduce the 
prevalence or mortality in the short term, but addition of a 
testing and treating intervention with 80% coverage could 
reduce deaths by 65%, and could avert 7·3 million deaths, 
including 1·5 million cancer deaths, between 2015 and 
2030, compared with status quo. Addition of a cure would 
not aﬀ ect incidence or mortality, if applied to people 
already on successful treatment.
This set of combined interventions would bring 
forward the date of elimination of new incident chronic 
infections and HBV-related deaths in all settings 
(ﬁ gure 3). Half of the world regions are projected to reach 
elimination of new incident chronic infections before 
2060 with the scale-up of this set of interventions. Time 
to elimination of HBV-related deaths is more hetero-
geneous, with some regions, such as western Europe, 
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Figure 3: Global impact of interventions against HBV
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elimination is not achieved by 2100. HBV=hepatitis B virus. PPT=peripartum antiviral therapy (for hepatitis B e antigen-positive mothers).
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achieving elimination of HBV-related deaths as early as 
2017, and regions in sub-Saharan Africa and Asia not 
reaching this threshold until closer to 2090. In both 
cases, the region projected to achieve elimination last is 
west Africa, where the burden is high, coverage of 
interventions is low, and population growth will lead to 
proportionately more mother-to-child transmission.
Sensitivity analysis revealed that even when using lower 
eﬃ  cacy rates of all interventions combined, the com-
prehensive package of interventions would still achieve 
substantial health gains and avert 18·4 million new 
incident chronic infections (vs 28 million with our default 
assumptions) and 4·7 million HBV-related deaths (vs 
7·3 million with our default assumptions) between 2015 
and 2030, compared with continuing at status quo 
(appendix p 44).
The projections of reductions in new HBV cases are most 
sensitive to a lower eﬃ  cacy of infant vaccination, as 
determined by the modelled loss of impact when using 
assumed lower levels of eﬃ  cacy. Reducing infant 
vaccination eﬃ  cacy from 95% to 88% would result in 
4·8 million (14%) more infections between 2015 and 2030 
than our baseline scenario. The next most important 
parameters are a low eﬃ  cacy of birth-dose vaccination on 
PMTCT in HBeAg-positive mothers and lower adherence 
rates to treatment which, when varied individually, would 
each result in around 1·8 million (5%) more infections than 
with the baseline scenario. Adherence to treatment has an 
impact on the number of new cases, because adherence is 
relied on to reduce mother-to-child transmission for some 
women. The projections of reduction in HBV-related 
mortality are most sensitive to a low rate of adherence to 
antiviral therapy. With a proportion of those on treatment 
successfully adhering of 65%, lower than our default 
assumption of 95% adherence, and no other assumptions 
changed, the projections suggest that there would be 
2·6 million (27%) more deaths between 2015 and 2030 than 
the projection with our default assumptions. This large 
eﬀ ect is because eﬀ ectiveness of treatment in reducing the 
progression to liver disease is closely linked to adherence. 
Other factors did not have substantial eﬀ ect on the 
projection of HBV-related mortality.
The global cost needed to meet these targets is forecast 
to peak at $7·5 billion annually and will average $5·5 billion 
per year between 2015 and 2030 (ﬁ gure 4). Most of the total 
cost would be for the screening (39%) and treatment 
components (59%) in 2025 (appendix p 38). Costs reduce 
rapidly to $4·7 billion per year in 2030 due to an initial 
period of screening completing and would decline further 
after 2030 as progressively fewer people would be in need 
of treatment because of the impact of the prevention 
interventions. With a cure, the costs reduce more rapidly. 
The total net present cost to 2030 of this strategy would be 
$88·7 billion, which would reduce to $83·7 billion if a cure 
was developed. The countries that might be most reliant 
on international ﬁ nancing are the low-income countries 
(LICs) and lower-middle-income countries (LMICs). The 
costs in these regions represent 45% of the global costs 
and peak at $3·4 billion per year.
The feasibility and method of scale-up might vary 
between regions. In sub-Saharan Africa, the number of 
people estimated to need treatment for HBV under this 
strategy is similar to the number of people who need 
treatment for HIV (ﬁ gure 4); whereas in Asia, the 
number of people who need treatment for HBV far 
exceeds that of HIV, with a ratio of greater than ten in 
some areas, and this intervention could bring a 
considerable challenge to health systems.
Discussion
Major progress has been made in the prevention of 
hepatitis B infection through vaccination, and we will 
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soon enter an era in which we will start reaping the 
rewards of a reduction in HBV deaths. However, 
maintenance of a business as usual approach will not 
end the epidemic and will lead to 17 million avoidable 
deaths over the next 15 years.
A comprehensive and ambitious package of inter-
ventions that tackle prevention and treatment could lead 
to a 90% reduction in incidence of new chronic infections 
and 65% reduction in worldwide mortality by 2030. This 
target could be achievable with global investment that 
peaks at $7·5 billion per year. In high-income and upper-
middle-income countries, programme costs could be 
largely funded through domestic resources, given the 
low cost of the interventions. These costs would also be 
substantially oﬀ set by reduced costs of caring for people 
with advanced liver disease, and are likely to provide 
positive return on investment, especially once 
productivity gains are considered (unpublished). In 
settings where patients pay for cost of treatment 
themselves, these interventions would also substantially 
reduce the risk of people experiencing catastrophic 
health expenditure.32,33 Conversely, international 
ﬁ nancing will probably need to supplement resources 
necessary for combating HBV in LICs and LMICs, which 
are estimated to represent a maximum annual cost of 
$3·4 billion per year. This investment is similar to or 
substantially smaller than forecasts for HIV funding, 
which were estimated to be $8·1 billion per year from 
donor governments in 2013,34 with a projection of 
$18·4 billion in LICs and LMICs needed in 2020 to end 
the AIDS epidemic.35 For HBV, the reduction in costs 
over time is assured because transmission is reduced by 
immunisation.
We have provided targets for control and elimination 
that can frame and prioritise further innovation and 
operations research that will be required to address three 
main challenges. First, the need to prioritise a reduction 
in mother-to-child transmission presents a major 
operational challenge because available interventions 
require the mother to attend prenatal care and the 
neonate to be given a vaccine within 24 h of birth. 
However, in sub-Saharan Africa and southeast Asia, 77% 
of women are estimated to have at least one antenatal 
visit and only 50% of deliveries in sub-Saharan Africa 
and 68% of deliveries in southeast Asia are attended by 
skilled health staﬀ .36 An additional challenge is that the 
birth-dose (monovalent) vaccine is not funded by Gavi, 
the Vaccine Alliance (formerly the Global Alliance for 
Vaccines and Immunizations), which does fund other 
important vaccines. New highly scalable strategies will be 
needed to reach mothers in time to give these 
interventions. One promising approach could be to 
follow the lead of HIV’s PMTCT Option B and B+, 
whereby antivirals (which might be continued in-
deﬁ nitely) are provided to the mother after an antenatal 
assessment, but an assessment of the eﬀ ectiveness and 
feasibility of such an approach is needed.
Second, the proposed strategy calls for an enormous 
scale-up of case ﬁ nding and delivery of antiviral 
therapy. Targets can be achieved in diﬀ erent ways for 
diﬀ erent regions, according to existing engagement 
with health systems and health-system capacity. In 
countries that have developed infrastructure and 
trained personnel for delivery of HIV care, especially 
in sub-Saharan Africa, vertical programmes could be 
expanded to deliver HBV interventions (ﬁ gure 4). The 
success of 15 million people worldwide on HIV 
antiviral treatments shows that achievement of such an 
ambition is feasible and further speciﬁ c trials and 
large-scale screening and treatment programmes, such 
as PROLIFICA37 in west Africa, will show how such 
operations could be delivered most eﬀ ectively and cost-
eﬀ ectively.38 Linkage between testing and treatment 
centres and long-term adherence to treatment should 
be investigated and, more generally, lessons should be 
drawn from the experience in HIV treatment scale-up, 
especially in monitoring and strengthening the cascade 
of care.
Third, progress towards development of a cure for 
HBV infection could be an important factor in reducing 
the scale of the projected costs. The ability of the virus to 
persist and integrate into the host genome has been the 
main barrier in the successful development of a curative 
treatment, but new drugs are being developed that 
promise to overcome this problem.39
Early mathematical models have investigated the 
burden of HBV-related morbidity and mortality at the 
global level40 and in high prevalence41 and low prevalence 
countries.42,43 However, these models do not fully reﬂ ect 
current understanding of the clinical behaviour of HBV 
and did not include testing and treatment interventions. 
Furthermore, in comparison with previous analyses, the 
dynamic and mechanistic structure of our model means 
that we can examine the current and historical burden of 
disease under diﬀ erent counterfactual conditions, and 
make future projections that take appropriate account of 
feedback between the impacts of treatment, infection, 
and vaccination.
The model is calibrated to existing estimates of 
prevalence (of HBsAg and HBeAg) and liver cancer 
mortality. However, because of a paucity of data, 
especially in sub-Saharan Africa, published estimates of 
prevalence are based on extensive model-based extrapo-
lation.13 Similarly, due to incomplete cause-of-death and 
cancer registry data, especially in sub-Saharan Africa,44 
estimates of HBV-related mortality also rely on statistical 
adjustments. Because of a scarcity of data and availability 
of reliable region-speciﬁ c estimates, our model groups 
countries within a region together, but this grouping is 
at the expense of obscuring between-country variation. 
We have used uncorrected vaccination coverage data 
reported to WHO, despite this being of unveriﬁ ed 
quality. Speciﬁ cally, concerns have been raised about 
reported birth-dose vaccine coverage values not 
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reﬂ ecting the fact that often a dose is not administered 
within the required 24 h period.45 Furthermore, the 
numbers of people receiving treatment for hepatitis B 
and regimens used worldwide are not collated at country 
and regional levels, especially in LICs and LMICs. 
Therefore, regions were classiﬁ ed using available data 
and expert knowledge in our model. Finally, we assumed 
a linear relationship between unit cost of the 
interventions and intervention coverage levels, which 
could underestimate the true costs, because access to 
populations that are hardest to reach is often more costly 
and scale-up costs would vary depending on existing 
country-level infrastructure.
The current global approach to tackle HBV—a 
reliance on infant vaccination—has brought enormous 
health gains, but a step-change in strategy will be 
needed to bring a target of HBV elimination within 
reach. This change must see a large increase in the 
proportion of births that beneﬁ t from a package of 
prevention interventions and in the proportion of 
people with chronic HBV carriage who are diagnosed 
and treated when eligible, as well as maintenance and 
expansion of infant vaccination programmes. This 
strategy will require substantial new innovations, but 
these innovations can be synergistic with developments 
in many other parts of the health system, especially in 
mother and child health, screening for HIV and non-
communicable diseases, and HIV treatment delivery. 
These targets are well aligned with forward-looking 
development goals that emphasise cross-health system 
strengthening, chronic diseases, and the alleviation of 
risk of catastrophic health expenditure. Generally, there 
should be substantial momentum towards making the 
successes of the HIV response, such as innovation to 
deliver a large reduction in mother-to-child 
transmission and provision of wide-scale treatment 
programmes, the rule rather than exception in global 
public health.34
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